Kodiak Sciences Inc. (NasdaqGM: KOD)
Health Care · Biotechnology · US
$99.88
+0.01% today · +760.9% 1Y
Kodiak Sciences Inc. (NasdaqGM: KOD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $6.26B and employs 141 people.
Over the last twelve months the share price has gained 760.9%, trading between 10.94 and 104.00.
Tweenvest scores Kodiak Sciences Inc. across four factors: quality 45/100, value 70/100. Its strongest factor is value.
KOD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $6.26B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.18
- Dividend yield
- —
- Beta (5Y)
- 2.04
- 52-week high
- $104.00
- 52-week low
- $10.94
- Avg volume (3M)
- —
- Shares outstanding
- 62.72M
- Employees
- 141
- Next earnings
- —
About Kodiak Sciences Inc.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
- ISIN
- US50015M1099
- Founded
- 2009
- Listed since
- Oct 4, 2018
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Iovance Biotherapeutics, Inc.NasdaqGM: IOVA | $6.62B | $14.53 | -0.62% |
| Grifols, S.A.BME: GRF | $6.62B | €10.02 | +1.42% |
| Immunovant, Inc.NasdaqGS: IMVT | $6.29B | $29.95 | -1.71% |
| GRAIL, Inc.NasdaqGS: GRAL | $6.28B | $136.54 | -2.87% |
| Rhythm Pharmaceuticals, Inc.NasdaqGM: RYTM | $6.25B | $91.27 | +0.54% |
| Kiniksa Pharmaceuticals International, plcNasdaqGS: KNSA | $6.22B | $80.51 | +0.92% |
| Biocon LimitedNSEI: BIOCON | $5.88B | Rs349.40 | -5.75% |
| CG Oncology, Inc.NasdaqGS: CGON | $5.66B | $63.85 | +0.05% |
Figures last refreshed Oct 11, 2026.